Skip to main content

Dr. Brian Dong, MD

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
11
In the NPI registry since
2015
Medicare patients seen, 2024
239

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2015Medical school: University of Louisville School of Medicine
  • 2015Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    KY license 51631
  • Internal Medicine Physician
    KY license 51631
  • Student in an Organized Health Care Education/Training Program

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
239
Services billed
748
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes15570
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes14863
Established patient office or other outpatient visit, 20-29 minutes5140
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes3938
New patient office or other outpatient visit, 60-74 minutes3232
Established patient office or other outpatient visit, 40-54 minutes3018
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes2826

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 32 companies reported 160 payments worth $10,156 in total to this clinician.

By type
Consulting Fee$5,970
Food and Beverage$4,174
Education$12.42

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jun 18, 2025Pfizer Inc.
Jun 18, 2025
Consulting Fee
IBRANCE · ONCOLOGY
$2,160
Feb 7, 2025AstraZeneca Pharmaceuticals LP
Feb 7, 2025
Consulting Fee
Truqap · Oncology
$2,010
Jun 18, 2025Pfizer Inc.
Jun 18, 2025
Consulting Fee
IBRANCE · ONCOLOGY
$1,800
Dec 18, 2025Gilead Sciences, Inc.
Dec 18, 2025
Education
Trodelvy · ONC · in-kind
Company’s description;4267481;G360;12665445
$12.42

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Kentucky →

Industry-funded research

Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $308,628 in research payments for these studies, mostly to the institutions running them.

  • CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
    AstraZeneca UK Limited
  • A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
    AstraZeneca Pharmaceuticals LP
  • A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
    AstraZeneca Pharmaceuticals LP
  • A phase 1 dose escalation and expansion study to evaluate safety tolerability pharmacokinetic pharmacodynamic and antitumor activity of PF07248144 in participants with advanced or metastatic solid tumors
    Pfizer Inc.
  • Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC
    Genentech, Inc.
  • A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in…
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Louisville

Sources

NPI registry (CMS NPPES, November 2026; record last updated September 29, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1366837874. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.